Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE-MOBILYZED belimumab study in highly sensitized kidney transplant candidates
NL-OMON59711Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belimumab in HLA sensitization, sponsored by Leiden University Medical Center. Started Mar 2026; status: recruiting.
02
Drugs
belimumab
03
Conditions
HLA sensitization
Beyond the preview
Go deeper on NL-OMON59711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59711.